Kathryn S Ivy1,2, P Brent Ferrell3,4. 1. Boston University School of Medicine, Boston, MA, USA. 2. Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA. 3. Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA. brent.ferrell@vanderbilt.edu. 4. Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN, USA. brent.ferrell@vanderbilt.edu.
Abstract
PURPOSE OF REVIEW: Immune dysregulation is a defining feature of myelodysplastic syndromes (MDS). Recently, several studies have further defined the complex role of immune alterations within MDS. Herein, we will summarize some of these findings and discuss the therapeutic strategies currently in development. RECENT FINDINGS: Immune alterations in MDS are complex, heterogeneous, and intertwined with clonal hematopoiesis and stromal cell dysfunction. Inflammation in MDS proceeds as a vicious cycle, mediated in large part by secreted factors, which induce cell death and activate innate immune signaling. Therapeutic targeting of this variable immune dysregulation has led to modest responses thus far, but incorporation of the growing repertoire of immunotherapy brings new potential for improved outcomes. The immune milieu is variable across the spectrum of MDS subtypes, with a changing balance of inflammatory and suppressive cellular forces from low- to high-risk disease.
PURPOSE OF REVIEW: Immune dysregulation is a defining feature of myelodysplastic syndromes (MDS). Recently, several studies have further defined the complex role of immune alterations within MDS. Herein, we will summarize some of these findings and discuss the therapeutic strategies currently in development. RECENT FINDINGS: Immune alterations in MDS are complex, heterogeneous, and intertwined with clonal hematopoiesis and stromal cell dysfunction. Inflammation in MDS proceeds as a vicious cycle, mediated in large part by secreted factors, which induce cell death and activate innate immune signaling. Therapeutic targeting of this variable immune dysregulation has led to modest responses thus far, but incorporation of the growing repertoire of immunotherapy brings new potential for improved outcomes. The immune milieu is variable across the spectrum of MDS subtypes, with a changing balance of inflammatory and suppressive cellular forces from low- to high-risk disease.
Entities:
Keywords:
Bone marrow microenvironment; Immune dysregulation; Immunotherapy; Inflammation; Myelodysplastic syndromes
Authors: Tony A Navas; Mani Mohindru; Myka Estes; Jing Ying Ma; Lubomir Sokol; Perry Pahanish; Simrit Parmar; Edwin Haghnazari; Li Zhou; Robert Collins; Irene Kerr; Aaron N Nguyen; Yin Xu; Leonidas C Platanias; Alan A List; Linda S Higgins; Amit Verma Journal: Blood Date: 2006-08-29 Impact factor: 22.113
Authors: Alyssa Carey; David K Edwards; Christopher A Eide; Laura Newell; Elie Traer; Bruno C Medeiros; Daniel A Pollyea; Michael W Deininger; Robert H Collins; Jeffrey W Tyner; Brian J Druker; Grover C Bagby; Shannon K McWeeney; Anupriya Agarwal Journal: Cell Rep Date: 2017-03-28 Impact factor: 9.423
Authors: G M Gersuk; C Beckham; M R Loken; P Kiener; J E Anderson; A Farrand; A B Troutt; J A Ledbetter; H J Deeg Journal: Br J Haematol Date: 1998-10 Impact factor: 6.998
Authors: Andrea Pellagatti; Noor Esoof; Fiona Watkins; Cordelia F Langford; David Vetrie; Lisa J Campbell; Carrie Fidler; James D Cavenagh; Helen Eagleton; Peter Gordon; Barrie Woodcock; Beena Pushkaran; Mark Kwan; James S Wainscoat; Jacqueline Boultwood Journal: Br J Haematol Date: 2004-06 Impact factor: 6.998
Authors: S D Mundle; P Venugopal; J D Cartlidge; D V Pandav; L Broady-Robinson; S Gezer; E L Robin; S R Rifkin; M Klein; D E Alston; B M Hernandez; D Rosi; S Alvi; V T Shetty; S A Gregory; A Raza Journal: Blood Date: 1996-10-01 Impact factor: 22.113
Authors: Bart L Scott; Aravind Ramakrishnan; Barry Storer; Pamela S Becker; Steve Petersdorf; Elihu H Estey; H Joachim Deeg Journal: Br J Haematol Date: 2010-01-07 Impact factor: 6.998
Authors: Kathryn I Sunthankar; Matthew T Jenkins; Candace H Cote; Sweta B Patel; Robert S Welner; P Brent Ferrell Journal: Leukemia Date: 2021-12-02 Impact factor: 12.883
Authors: Hanneke J C M Wouters; Annette Conrads-Frank; Karin A Koinig; Alex Smith; Ge Yu; Theo de Witte; Bruce H R Wolffenbuttel; Gerwin Huls; Uwe Siebert; Reinhard Stauder; Melanie M van der Klauw Journal: Ann Hematol Date: 2021-09-02 Impact factor: 4.030